Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03729739
Other study ID # 1-10-72-263-18
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 6, 2018
Est. completion date December 31, 2025

Study information

Verified date March 2024
Source Aarhus University Hospital Skejby
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. QFR is estimated based on two angiographic projections. Studies have shown a good correlation with the present wire-based standard approach Fractional Flow Reserve (FFR) for assessment of intermediate coronary stenosis. The purpose of the FAVOR III Europe Japan study is to investigate if a QFR-based diagnostic strategy will results in non-inferior clinical outcome after 12 months compared to a standard pressure-wire guided strategy in evaluation of patients with chest pain (stable angina pectoris) and intermediate coronary stenosis.


Description:

Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional significance by fractional flow reserve has been shown to improve clinical outcome, to reduce number of stents implanted, and has obtained the highest recommendation in European guidelines. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperaemia). The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measurements have supported adoption of an FFR based strategy but the need for interrogating the stenosis by a pressure wire, the small risks associated hereto, the cost of the wire, and the drug inducing hyperaemia has limited more widespread adoption. Quantitative Flow Ratio is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. Two multi-center studies, the FAVOR II Europe-Japan and China studies evaluated the feasibility and diagnostic performance of in-procedure QFR, showing very good agreement between QFR and FFR. The purpose of the FAVOR III Europe Japan study is to investigate if a QFR-based diagnostic strategy yields non-inferior 12-month clinical outcome compared to a standard pressure-wire guided strategy in evaluation of patients with stable angina pectoris and intermediate coronary stenosis. Primary hypothesis: A QFR based diagnostic strategy results in non-inferior clinical outcome, assessed by a composite endpoint of all cause death, non-fatal myocardial infarction (MI) and unplanned revascularization after one year, compared to a strategy of pressure wire-based FFR for assessment of physiological significance of intermediate coronary artery stenosis. Methods: Investigator initiated, 1:1 randomized, prospective, clinical outcome, non-inferiority, multi-center trial performed at up to 40 international sites with inclusion of 2000 patients. Patients with stable angina pectoris or need for evaluation of non-culprit lesions after acute MI are enrolled. At least two angiographic projections are acquired during resting conditions. If the angiographic criteria are met, the patient is randomized to either a QFR- or an FFR-based diagnostic strategy. Revascularization is performed according to best standard by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Patient follow-up is continued until 24 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2001
Est. completion date December 31, 2025
Est. primary completion date July 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age of 18 years and above - Both genders - Indication for invasive coronary angiography - Patients with stable angina pectoris, or assessment of secondary lesions in stabilized non-STEMI patients or assessment of secondary lesions in patients with prior STEMI and staged evaluation of secondary lesions. - Able to provide written informed consent Angiographic inclusion criteria - Diameter stenosis of 40-90% diameter stenosis - Vessel diameter of at least 2.5 mm and supplying viable myocardium - Patients with restenosis in a native coronary artery can be included Exclusion Criteria: - Severely impaired renal function: Glomerular filtration rate (GFR) < 20 mL/min/1.73m² - Life expectancy less than one year - Cardiogenic shock or unstable haemodynamic state (Killip class III and IV) - ST-elevation myocardial infarction (STEMI) within 72 hours - Bypass graft to any target vessel - Atrial fibrillation at the time of the procedure - Chronic total occlusions of any vessel with possible or established indication for treatment - Pregnancy or intention to become pregnant during the course of the trial - Breast feeding - Planned need for concomitant valvular or aortic surgery - Left ventricular ejection fraction (LVEF) < 30% - Previous inclusion in the FAVOR III trial - Enrolled in another clinical study, and for this reason not treated according to present European Society of Cardiology guidelines, or the protocol treatment conflicts with the protocol treatment of FAVOR III - Inability to tolerate contrast media - Inability to tolerate Adenosine Angiographic exclusion criteria - Ostial right coronary artery > 50% diameter stenosis - Left main coronary artery > 50% diameter stenosis - Lesions properties indicative of myocardial bridging - Bifurcation lesions with major (>1 mm) step down in reference size across the bifurcation - Severe tortuosity of any target vessel - Severe overlap in the stenosed segment - Poor image quality precluding identification of vessel contours

Study Design


Intervention

Diagnostic Test:
QFR-based diagnostic strategy
Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
FFR-based diagnostic strategy
Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions

Locations

Country Name City State
Denmark Aalborg University Hospital Aalborg
Denmark Aarhus University Hospital Aarhus N
Denmark Gentofte Hospital Hellerup
France GCS ES Axium - Parc Rambot Aix-en-Provence
France CHU de Lille, Lille University Hospital Lille
France Institut Cardiovasculaire Paris Sud (ICPS), Hopital Jacques Cartier Massy
France Hopital Haut-Leveque, Pessac Pessac
France Hôpital Privé Claude Galien Quincy
France Institut Arnault Tzanck Saint-Laurent-du-Var Nice
France Clinique Pasteur, Toulouse Toulouse
Germany Charite-Universitatsmedizin Berlin Berlin
Germany Elisabeth Krankenhaus Essen
Germany University Clinic Leipzig Leipzig
Italy Ospedale Maggiore, AUSL Bologna Bologna
Italy Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara Ferrara
Italy Azienda Ospedaliero Universitaria Federico II di Napoli Naples
Italy San Luigi Gonzaga University Hospital, Turin Orbassano
Italy Arcispedale S. Maria Nuova di Reggio Emilia Reggio Emilia
Italy Ospedale degli Infermi di Rimini Rimini
Italy Ospedale di Rivoli, Torino Torino
Italy Azienda Ospedaliera Universitaria integrata Verona Verona
Latvia Riga Stradini University Hospital Riga
Lithuania Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas
Netherlands Academic Medical Center (AMC) Amsterdam
Netherlands VU University Medical Center Amsterdam
Netherlands HagaZiekenhuis The Hague
Poland Medical University of Warsaw Warsaw
Spain Hospital Clinico de Coruña Coruña
Spain Hospital Clinico Universitario Virgen de la Arrixaca El Palmar Murcia
Spain Hospital Lucus Agusti LUGO Lugo
Spain Hospital Clinico San Carlos Madrid
Spain Hospital Clinico Universitario de Valladolid Valladolid
Spain Hospital Álvaro Cunqueiro Vigo
Sweden Sahlgrenska University Hospital Göteborg
Switzerland Barbera Stähli Zürich Zûrich

Sponsors (2)

Lead Sponsor Collaborator
Aarhus University Hospital Skejby Medis Medical Imaging Systems

Countries where clinical trial is conducted

Denmark,  France,  Germany,  Italy,  Latvia,  Lithuania,  Netherlands,  Poland,  Spain,  Sweden,  Switzerland, 

References & Publications (4)

Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JHC, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013. — View Citation

Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Botker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J Am Heart Assoc. 2018 Jul 6;7(14):e009603. doi: 10.1161/JAHA.118.009603. — View Citation

Westra J, Tu S, Winther S, Nissen L, Vestergaard MB, Andersen BK, Holck EN, Fox Maule C, Johansen JK, Andreasen LN, Simonsen JK, Zhang Y, Kristensen SD, Maeng M, Kaltoft A, Terkelsen CJ, Krusell LR, Jakobsen L, Reiber JHC, Lassen JF, Bottcher M, Botker HE, Christiansen EH, Holm NR. Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II). Circ Cardiovasc Imaging. 2018 Mar;11(3):e007107. doi: 10.1161/CIRCIMAGING.117.007107. — View Citation

Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Patient oriented composite endpoint (PoCE) A composite endpoint of 1) all-cause mortality, 2) any myocardial infarction, and 3) any unplanned revascularization 12 months
Secondary Target vessel failure A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization. 1 month
Secondary Target vessel failure A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization. 12 months
Secondary Target vessel failure A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization. 24 months
Secondary All-cause mortality Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons. 1 month
Secondary All-cause mortality Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons. 12 months
Secondary All-cause mortality Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons. 24 months
Secondary Cardiac death Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death 1 month
Secondary Cardiac death Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death 12 months
Secondary Cardiac death Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death 24 months
Secondary Myocardial infarction Procedure and non-procedure related myocardial infarction. Protocol defined. 1 month
Secondary Myocardial infarction Procedure and non-procedure related myocardial infarction. Protocol defined. 12 months
Secondary Myocardial infarction Procedure and non-procedure related myocardial infarction. Protocol defined. 24 months
Secondary Target vessel myocardial infarction As "any myocardial infarction", but with culprit lesion in index vessel. 1 month
Secondary Target vessel myocardial infarction As "any myocardial infarction", but with culprit lesion in index vessel. 12 months
Secondary Target vessel myocardial infarction As "any myocardial infarction", but with culprit lesion in index vessel. 24 months
Secondary Any unplanned revascularization Coronary artery bypass grafting (CABG) or PCI of any lesion.
Planned Revascularization:
Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated.
Unplanned Revascularization:
Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
1 month
Secondary Any unplanned revascularization Coronary artery bypass grafting (CABG) or PCI of any lesion.
Planned Revascularization:
Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated.
Unplanned Revascularization:
Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
12 months
Secondary Any unplanned revascularization Coronary artery bypass grafting (CABG) or PCI of any lesion.
Planned Revascularization:
Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated.
Unplanned Revascularization:
Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
24 months
Secondary Any ischemia driven de novo revascularization Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 1 month
Secondary Any ischemia driven de novo revascularization Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 12 months
Secondary Any ischemia driven de novo revascularization Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 24 months
Secondary Ischemia driven target vessel revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 1 month
Secondary Ischemia driven target vessel revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 12 months
Secondary Ischemia driven target vessel revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 24 months
Secondary Ischemia driven treated target lesion revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 1 month
Secondary Ischemia driven treated target lesion revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 12 months
Secondary Ischemia driven treated target lesion revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI 24 months
Secondary Ischemia driven, measured segment revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 1 month
Secondary Ischemia driven, measured segment revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR (both treated and not treated). In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 12 months
Secondary Ischemia driven, measured segment revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 24 months
Secondary Ischemia driven measured segment de novo revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 1 month
Secondary Ischemia driven measured segment de novo revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 12 months
Secondary Ischemia driven measured segment de novo revascularization Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI. 24 months
Secondary Feasibility of QFR Percentage of successful QFR in patients allocated to a QFR based diagnostic strategy 1 hour
Secondary Feasibility of FFR Percentage of successfully performed FFR measurements in vessels with attempted FFR (vessel level) Percentages of patients with successful FFR measurements (all attempted) 1 hour
Secondary Number of lesion interrogated Total number of lesions diagnosed with either QFR or FFR during the procedure 1 hour
Secondary Procedure time Time from introduction of the sheet until the sheet for coronary access is removed from the patient 1 hour
Secondary Contrast volume Total volume of contrast used in the procedure 1 hour
Secondary Fluoroscopy time Total fluoroscopy time for the procedure 1 hour
Secondary Number of stents implanted Total number of stents implanted during the procedure. Stents implanted in a staged procedure are included 1 hour
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A